Lundbeck

HLUYY

N/A

NASDAQHealthcare🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Feb 28, 2026

21d

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

3 upcoming, 0 past

Phase 2Next

Lu AG09222 Phase 2 Results Expected

Feb 28, 2026Lu AG09222874

Primary completion for Lu AG09222 trial (NCT06323928) in Migraine

Source

⭐Phase 3

Eptinezumab Phase 3 Results Expected

Sep 5, 2026Eptinezumab285

Primary completion for Eptinezumab trial (NCT04965675) in Chronic Migraine in Children

Source

Phase 2

Lu AG13909 Phase 2 Results Expected

Sep 30, 2026Lu AG1390942

Primary completion for Lu AG13909 trial (NCT05669950) in Congenital Adrenal Hyperplasia

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Escitalopram 10-20 mg

Phase 3

Major Depressive Disorder

Clobazam Low Dose

Phase 3

Epilepsy

Quetiapine

Phase 3

Schizophrenia

Lu AA21004

Phase 3

Generalized Anxiety Disorder

Risperidone

Phase 3

Schizophrenia

Vortioxetine 10 mg

Phase 3

Major Depressive Disorder

Venlafaxine extended release

Phase 3

Major Depressive Disorder

MK0928, gaboxadol / Duration of Treatment - 1 year

Phase 3

Insomnia

Aripiprazole once-monthly

Phase 3

Schizophrenia

Idalopirdine 60 mg

Phase 3

Alzheimer's Disease

Azilect®

Phase 3

Parkinson's Disease

Bendamustine at a dose of 100 mg/m2

Phase 3

Indolent Non-Hodgkin's Lymphoma

Agomelatine

Phase 3

Major Depressive Disorder

Vortioxetine (Lu AA21004)

Phase 3

Major Depressive Disorder

Lu AF82422

Phase 3

Multiple System Atrophy

Desmoteplase

Phase 3

Acute Ischemic Stroke

Adjunct brexpiprazole

Phase 3

Major Depression Disorder

ADT

Phase 3

Major Depressive Disorder

Vortioxetine 10-20 mg

Phase 3

Major Depressive Disorder

Sertindole

Phase 3

Schizophrenia

Intravenous Carbamazepine (IV CBZ)

Phase 3

Epilepsy

Brexpiprazole

Phase 3

Schizophrenia

MK0928, gaboxadol

Phase 3

Insomnia

Aripiprazole and aripiprazole once-monthly

Phase 3

Schizophrenia

Nalmefene

Phase 3

Alcohol Dependence

Clobazam Medium Dose

Phase 3

Epilepsy

Clobazam

Phase 3

Lennox-Gastaut Syndrome

Vortioxetine 10 mg/day

Phase 3

Depressive Disorder, Major

gaboxadol

Phase 3

Insomnia

rasagiline

Phase 3

Parkinson's Disease

Eptinezumab

Phase 3

Chronic Migraine in Children

Zicronapine

Phase 3

Schizophrenia

Quetiapine extended release

Phase 3

Schizophrenia

Vortioxetine 20 mg/day

Phase 3

Depressive Disorder, Major

Olanzapine

Phase 3

Schizophrenia

Idalopirdine

Phase 3

Alzheimer's Disease

Duloxetine

Phase 3

Major Depressive Disorder

Vortioxetine

Phase 3

Depressive Disorder, Major

Lu AF35700

Phase 3

Schizophrenia

Lu AG09222

Phase 2

Migraine

Lu AG13909

Phase 2

Congenital Adrenal Hyperplasia

MK0928, gaboxadol / Duration of Treatment 3 Weeks

Phase 2

Primary Insomnia

Vortioxetine (IV)

Phase 2

Depressive Disorder, Major

Lu AA24530

Phase 2

Major Depressive Disorder

vortioxetine 10 mg tablet

Phase 2

Attention Deficit Hyperactivity Disorder

Escitalopram 20 mg

Phase 2

Major Depressive Disorder

Vortioxetine infusion 25 mg

Phase 2

Major Depressive Disorder

Lu AA24493

Phase 2

Friedreich's Ataxia

Zicronapine open-label lead-in 10 mg daily

Phase 2

Schizophrenia

Venlafaxine XL

Phase 2

Major Depressive Disorder

Lu AE58054

Phase 2

Schizophrenia

Melperone HCl

Phase 2

Parkinson's Disease

Drug Name	Phase	Indication	Designations
Escitalopram 10-20 mg	Phase 3	Major Depressive Disorder	-
Clobazam Low Dose	Phase 3	Epilepsy	-
Quetiapine	Phase 3	Schizophrenia	-
Lu AA21004	Phase 3	Generalized Anxiety Disorder	-
Risperidone	Phase 3	Schizophrenia	-
Vortioxetine 10 mg	Phase 3	Major Depressive Disorder	-
Venlafaxine extended release	Phase 3	Major Depressive Disorder	-
MK0928, gaboxadol / Duration of Treatment - 1 year	Phase 3	Insomnia	-
Aripiprazole once-monthly	Phase 3	Schizophrenia	-
Idalopirdine 60 mg	Phase 3	Alzheimer's Disease	-
Azilect®	Phase 3	Parkinson's Disease	-
Bendamustine at a dose of 100 mg/m2	Phase 3	Indolent Non-Hodgkin's Lymphoma	-
Agomelatine	Phase 3	Major Depressive Disorder	-
Vortioxetine (Lu AA21004)	Phase 3	Major Depressive Disorder	-
Lu AF82422	Phase 3	Multiple System Atrophy	-
Desmoteplase	Phase 3	Acute Ischemic Stroke	-
Adjunct brexpiprazole	Phase 3	Major Depression Disorder	-
ADT	Phase 3	Major Depressive Disorder	-
Vortioxetine 10-20 mg	Phase 3	Major Depressive Disorder	-
Sertindole	Phase 3	Schizophrenia	-
Intravenous Carbamazepine (IV CBZ)	Phase 3	Epilepsy	-
Brexpiprazole	Phase 3	Schizophrenia	-
MK0928, gaboxadol	Phase 3	Insomnia	-
Aripiprazole and aripiprazole once-monthly	Phase 3	Schizophrenia	-
Nalmefene	Phase 3	Alcohol Dependence	-
Clobazam Medium Dose	Phase 3	Epilepsy	-
Clobazam	Phase 3	Lennox-Gastaut Syndrome	-
Vortioxetine 10 mg/day	Phase 3	Depressive Disorder, Major	-
gaboxadol	Phase 3	Insomnia	-
rasagiline	Phase 3	Parkinson's Disease	-
Eptinezumab	Phase 3	Chronic Migraine in Children	-
Zicronapine	Phase 3	Schizophrenia	-
Quetiapine extended release	Phase 3	Schizophrenia	-
Vortioxetine 20 mg/day	Phase 3	Depressive Disorder, Major	-
Olanzapine	Phase 3	Schizophrenia	-
Idalopirdine	Phase 3	Alzheimer's Disease	-
Duloxetine	Phase 3	Major Depressive Disorder	-
Vortioxetine	Phase 3	Depressive Disorder, Major	-
Lu AF35700	Phase 3	Schizophrenia	-
Lu AG09222	Phase 2	Migraine	-
Lu AG13909	Phase 2	Congenital Adrenal Hyperplasia	-
MK0928, gaboxadol / Duration of Treatment 3 Weeks	Phase 2	Primary Insomnia	-
Vortioxetine (IV)	Phase 2	Depressive Disorder, Major	-
Lu AA24530	Phase 2	Major Depressive Disorder	-
vortioxetine 10 mg tablet	Phase 2	Attention Deficit Hyperactivity Disorder	-
Escitalopram 20 mg	Phase 2	Major Depressive Disorder	-
Vortioxetine infusion 25 mg	Phase 2	Major Depressive Disorder	-
Lu AA24493	Phase 2	Friedreich's Ataxia	-
Zicronapine open-label lead-in 10 mg daily	Phase 2	Schizophrenia	-
Venlafaxine XL	Phase 2	Major Depressive Disorder	-
Lu AE58054	Phase 2	Schizophrenia	-
Melperone HCl	Phase 2	Parkinson's Disease	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

HLUYY News